BIVM-ERCC5 readthrough (BIVM-ERCC5)

BIVM-ERCC5 readthrough is a naturally occurring read-through transcript that joins the neighboring BIVM (basic, immunoglobulin-like variable motif containing) and ERCC5 (excision repair cross-complementing rodent repair deficiency, complementation group 5) genes on chromosome 13. This fusion transcript encodes a protein sharing sequence identity with the products of each individual gene. There is no direct evidence that the BIVM-ERCC5 fusion functions as a therapeutic target, enzyme, receptor, transporter, or is directly implicated in disease beyond being a readthrough product of two protein-coding genes[1][2][4][7][8]. Key points: - BIVM-ERCC5 is not a well-established therapeutic target: It is not annotated as an actionable receptor, enzyme, transporter, or similar. - The locus exists as a readthrough/fusion event rather than a distinct canonical protein with defined functional or disease associations. - Most disease, function, and drug-interacting information applies to ERCC5, not the BIVM-ERCC5 readthrough specifically[3][6]. - There are no known approved drugs, mechanisms of action, or biomarker utility specifically attributed to the BIVM-ERCC5 readthrough transcript or protein. - Aliases include ERCC5-202 and "BIVM-ERCC5 protein." - Because it is a readthrough annotation rather than a discrete, actionable target, there is some ambiguity and it may not be suitable for use as a structured drug target entry[2][4].

Other names

ERCC5-202BIVM-ERCC5 protein